Mitogen-activated protein kinase kinase kinase 7 (MAP3K7) (MAP3K7)

Mitogen-activated protein kinase kinase kinase 7 (MAP3K7), also known as Transforming growth factor-beta-activated kinase 1 (TAK1), is a critical serine/threonine kinase that serves as a central integrator for signaling pathways initiated by TGF-beta, Toll-like receptors (TLRs), and various cytokine receptors (UniProt P45985). It is activated by upstream nodes, including IRAK1/4 and TRAF6, which facilitate its recruitment to signaling complexes via polyubiquitin chains (PubMed: 29109494). Once active, MAP3K7 phosphorylates and activates the IKK complex and MKK4/7, leading to the activation of NF-kappaB and MAPK pathways, which drive the expression of pro-inflammatory cytokines and cell survival factors (PubMed: 21115689). Due to its role in promoting inflammation and cell survival, MAP3K7 is a target for treating autoimmune disorders like rheumatoid arthritis and various cancers where it contributes to chemoresistance (PubMed: 28334779). However, systemic inhibition of MAP3K7 is associated with significant safety concerns, including hepatotoxicity and unintended cell death, because it also functions to protect cells from TNF-alpha-induced apoptosis (PubMed: 25114208). Experimental inhibitors like Takinib have shown promise in selectively targeting this node to modulate inflammatory signaling (PubMed: 28816321). The complexity of its upstream regulation by nodes like IRAK and TRAF proteins makes it a focal point for understanding multi-protein signaling hubs in inflammatory disease.

Other names

Transforming growth factor-beta-activated kinase 1TAK1TGF-beta-activated kinase 1MEKK7

Small molecule inhibitors bind to the ATP-binding pocket of MAP3K7 (TAK1), preventing its autophosphorylation and subsequent activation of the IKK complex and MKK4/7, thereby suppressing the production of pro-inflammatory cytokines and promoting apoptosis in sensitive cells.